News Sentiment

AQST sentiment intelligence

Aquestive Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 4.12 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-1.4% over one week, -1.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Form 144 Aquestive Therapeutics For: 15 July By Investing.com

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.4% Price digesting
Trend fit Trend inactive -1.2% over four weeks
Fair value 12.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 30
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
ACCESS Newswire 9
simplywall.st 6
Investing.com Canada 3
TradingView 3
Seeking Alpha 2
GlobeNewswire 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 11
Regulatory and legal 11
Analyst action 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Investing.com Canada Direct company coverage

Form 144 Aquestive Therapeutics For: 15 July By Investing.com

This article from Investing.com announces a Form 144 filing for Aquestive Therapeutics on July 15. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates of Aquestive Therapeutics plan to sell shares. The brief piece provides limi

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 01:45
Source
Investing.com Canada
TradingView Direct company coverage

Price to earnings forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST

This article provides financial information for Aquestive Therapeutics, Inc. (NASDAQ: AQST), specifically focusing on its forward price-to-earnings ratio. It is presented on TradingView, a platform offering various financial tools and market data.

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 17:45
Source
TradingView
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and cont

Tone
Negative 19/100
Event
Regulatory and legal
Published
14 Jul 2026 11:00
Source
ACCESS Newswire
TradingKey Direct company coverage

Aquestive Therapeutics Inc (AQST) Institutional Confidence

Aquestive Therapeutics Inc (AQST) has an institutional shareholding score of 5.00, placing it 73rd in the Pharmaceuticals industry. Institutional investors collectively hold 60.30% of the company's shares, an increase of 16.75% quarter-over-quarter. Bill Nygren of OAKMX is the la

Tone
Positive 66/100
Event
Market update
Published
13 Jul 2026 13:43
Source
TradingKey
ACCESS Newswire Direct company coverage

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST) and its officers. The firm is encouraging shareholders who purchased AQST securities before June 16, 2025, and still hold them, to contact t

Tone
Negative 30/100
Event
Regulatory and legal
Published
13 Jul 2026 02:10
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) concerning possible corporate wrongdoing by its officers and/or directors. The firm encourages investors who purchased Aquestive securities before June 16, 2025, and s

Tone
Negative 29/100
Event
Market update
Published
10 Jul 2026 06:09
Source
ACCESS Newswire
Investing News Network Direct company coverage

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Aquestive Therapeutics, a pharmaceutical company, will attend the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14, 2026, where its management team will host 1x1 investor meetings. The forum will focus on key therapeutic themes in immunology, inflammation, and m

Tone
Positive 59/100
Event
Market update
Published
07 Jul 2026 12:39
Source
Investing News Network
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) securities who bought prior to June 16, 2025, and still hold them. The investigation focuses on whether Aquestive and its officers/directors engaged

Tone
Negative 19/100
Event
Regulatory and legal
Published
07 Jul 2026 11:00
Source
ACCESS Newswire
Stock Titan Direct company coverage

If You Invested $1,000 in Aquestive Therapeutics (AQST)

This article analyzes the historical performance of an imagined $1,000 investment in Aquestive Therapeutics (AQST) over one, five, and ten-year periods, showing the total returns and compound annual growth rates. It details Aquestive Therapeutics' business model, proprietary tech

Tone
Neutral 50/100
Event
Macro sensitivity
Published
04 Jul 2026 00:09
Source
Stock Titan
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages Aquestive stockholders who purchased securities before June 16, 2025, and still hold them, to contact them for more information and to a

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 02:41
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to a

Tone
Negative 25/100
Event
Regulatory and legal
Published
30 Jun 2026 11:00
Source
ACCESS Newswire
Quantisnow Direct company coverage

SEC Form S-3 filed by Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc. (AQST) filed an S-3 form with the SEC, which was promptly reported by Quantisnow. Quantisnow is a real-time market data and news platform that provides alerts on SEC filings, FDA approvals, analyst ratings, and insider trades to retail investors. The a

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 19:41
Source
Quantisnow
Investing.com Canada Direct company coverage

Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com

This article reports on the filing of Form S-3 by Aquestive Therapeutics Inc. on June 26. The brief notice indicates a regulatory filing related to the company, suggesting potential corporate actions such as a stock offering.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
26 Jun 2026 20:40
Source
Investing.com Canada
TradingView Direct company coverage

AQST Stock Price and Chart — NASDAQ:AQST

This page provides a comprehensive overview of Aquestive Therapeutics, Inc. (AQST) stock, including its current price, performance across various timeframes, key financial statistics, and upcoming earnings dates. It also features a collection of trading ideas and analyses from th

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST)

This article provides an overview of Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock, including its current price, market capitalization, analyst forecasts, and historical performance. It also details recent financial actuals such as earnings per share and revenue, and forthcom

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether the company's officers and/or directo

Tone
Negative 29/100
Event
Regulatory and legal
Published
25 Jun 2026 15:10
Source
The National Law Review
Investing.com Nigeria Direct company coverage

Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com

This article reports on a Form 4 filing for Aquestive Therapeutics Inc. submitted on June 24th. The filing indicates insider transactions for the company (AQST). The article provides no further details beyond the existence of the filing and some financial data unrelated to the sp

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 06:12
Source
Investing.com Nigeria
Investing.com Canada Direct company coverage

Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com

Aquestive Therapeutics director Julie Krop sold $125,392 worth of company stock, involving 25,000 shares at $5.0157 per share, following the exercise of stock options. The sale was executed under a Rule 10b5-1 trading plan, occurring after the stock saw a 57% surge over the past

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 15:41
Source
Investing.com Canada
Market source Direct company coverage

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Aquestive Therapeutics (AQST) saw a 6.6% stock rally, closing at $5.03, driven by investor confidence in its lead product candidate, Anaphylm, and its development pipeline. The company plans to resubmit its NDA for Anaphylm in Q3 2026 and is also advancing AQST-108. Despite robus

Tone
Positive 64/100
Event
Market update
Published
24 Jun 2026 04:32
Source
Market source
Pharma Voice Direct company coverage

Does US manufacturing give drugmakers a speed edge?

Aquestive Therapeutics' quick resolution of an FDA rejection for Anaphylm, thanks to its U.S.-based manufacturing, highlights the speed advantages of domestic operations. This article explores how proximity to facilities can significantly cut down response times and complexities

Tone
Positive 73/100
Event
Market update
Published
23 Jun 2026 13:40
Source
Pharma Voice
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST). The firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with

Tone
Negative 28/100
Event
Regulatory and legal
Published
23 Jun 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Aquestive Therapeutics, Inc. (AQST) regarding alleged corporate wrongdoing. The firm encourages Aquestive shareholders who purchased securities before June 16, 2025, and still hold them, to co

Tone
Negative 25/100
Event
Regulatory and legal
Published
21 Jun 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities before June 16, 2025, and continue to hold them. The firm is looking into possible corporate wrongdoing by Aquestive's

Tone
Negative 27/100
Event
Market update
Published
19 Jun 2026 16:09
Source
ACCESS Newswire
Sahm Direct company coverage

Have Aquestive Therapeutics Insiders Been Selling Stock?

A recent analysis indicates that insiders at Aquestive Therapeutics (NASDAQ:AQST) have been selling stock, with CEO Daniel Barber divesting US$104k worth of shares, representing 3.8% of his holdings. This follows an earlier, larger sale of US$754k. Despite these sales, insiders s

Tone
Negative 36/100
Event
Market update
Published
18 Jun 2026 16:09
Source
Sahm